Part I. Design of a novel class of reversible non-covalent small molecule inhibitors for human Granzyme B (hGrB) Part II. Curcumin and mimics as proteasome inhibitors Part III. Design of novel coactivator binding inhibitors (CBIs) for the estrogen receptor α : break the 1µM barrier

Towards the Development of Non-Toxic Therapeutics in the Fight Against Cancer

Use of Furans as Vehicles for Heterocyclic Synthesis: Anaza-Achmatowicz Approach to Piperidine Alkaloids, a Novel OxidativeRoute to Acyloxypyrrolinones, and IMDAF Studies Toward a Synthesisof Minfiensine and Morphine

Part I: Design, Synthesis and Biological Evaluation of C6-C8 Bridged Epothilone AnalogsPart II: Discovery of Small Molecule CXCR4 Antagonists

Engineering The Substrate Specificity Of Human Deoxycytidine Kinase

Computer-Assisted Drug Discovery Part I: Design, Development, Validation and Application of FRESH, a Novel In-Silico High-throughput Screening Program Part II: Monocarbonyl Curcumin Analogues: Heterocyclic Pleiotropic Kinase Inhibitors that Mediate Anticancer Properties Part III: Development of 2nd Generation NAMFIS Software Program by Java

Design, Synthesis and Biological Evaluation of C4-C9 Bridged Epothilone Analogs

Navigating the Roads to Drug Discovery: Part 1: Design, Synthesis, and Biological Evaluation of a Novel Class of Allosteric Modulators of N-Methyl-D-Aspartate Receptor Function Part 2: Discovery of Novel Tetrahydroisoquinoline (THIQ)-Based CXCR4 Antagonists and Conformational Analysis of Structurally Similar CXCR4 Antagonists

Generating designer enzymes for therapeutic and industrial applications